RT Journal Article SR Electronic T1 Evaluation of a novel antihypertensive agent, LY127210, in anesthetized and conscious spontaneously hypertensive rats. JF Journal of Pharmacology and Experimental Therapeutics JO J Pharmacol Exp Ther FD American Society for Pharmacology and Experimental Therapeutics SP 134 OP 138 VO 232 IS 1 A1 R R Ruffolo, Jr A1 K Kurz A1 C J Paget YR 1985 UL http://jpet.aspetjournals.org/content/232/1/134.abstract AB LY127210 (7,8-dimethoxy-1H-3-benzazepin-2-amine, hydrochloride) is a novel peripheral arterial vasodilator that reduces mean arterial blood pressure in anesthetized and conscious spontaneously hypertensive rats by all conventional routes of administration. The antihypertensive activity of LY127210 results predominantly from a decrease in total peripheral vascular resistance, and the degree of reflex tachycardia produced by LY127210 in conscious spontaneously hypertensive rats is significantly less than that produced by hydralazine at equivalent antihypertensive doses. The relative lack of reflex tachycardia produced by LY127210 appears to result from a direct bradycardic effect of the compound that occurs at the level of the myocardium at doses similar to those required to produce peripheral arteriolar vasodilation. It is proposed that the direct bradycardic effect of LY127210 serves to offset, at least in part, the tachycardia resulting from reflex stimulation of sympathetic outflow that occurs upon activation of the baroreflex loop as blood pressure is lowered. The results indicate that LY127210 may provide adequate control of blood pressure and may not require the concomitant administration of a beta-adrenoceptor antagonist to control reflex tachycardia, as is commonly necessary with hydralazine.